TABLE 3.
Variant clone drug sensitivity and replication capacity at baseline and CVW
| Patient | Study visita | Integrase-linked substitution(s) | No. of clones | Fold change in median drug sensitivityb |
Median replication capacity (%)c | ||
|---|---|---|---|---|---|---|---|
| Dolutegravird | Elvitegravire | Raltegravirf | |||||
| 1 | Baseline | Wild-type | 5 | 0.87 | 1 | 0.88 | 81 |
| R263K | 3 | 1.81 | 2.85 | 1.09 | 27 | ||
| CVW (wk 36) | Wild-type | 8 | 0.77 | 0.86 | 0.89 | 78 | |
| 2 | Baseline | Wild-type | 7 | 0.93 | 1.94 | 1.18 | 67 |
| T66I | 1 | 0.33 | 13 | 0.58 | 12 | ||
| CVW (wk 36) | G118R | 8 | 30.5 | 26.5 | 24 | 9.55 | |
| 3 | Baseline | Wild-type | 16 | 1.08 | 1.03 | 1.03 | 91 |
| CVW (wk 48) | H51Y, G118R | 3 | 11 | 10 | 4.43 | 28 | |
| G118R, E138K, R263K | 13 | 13 | 11 | 2.03 | 27 | ||
a
CVW, confirmed virologic withdrawal.
b
Fold change in half-maximal inhibitory concentration relative to the wild-type value.
c
Values are relative to wild-type replication.
d
The clinical cutoff for dolutegravir is 4.0.
e
The biological cutoff for elvitegravir is 2.5.
f
The biological cutoff for raltegravir is 1.5.